TScan Therapeutics (TCRX) Return on Sales (2020 - 2026)

TScan Therapeutics (TCRX) has 7 years of Return on Sales data on file, last reported at 0.29% in Q1 2026.

• On a quarterly basis, Return on Sales fell 12.0% year-over-year to 0.29% in Q1 2026; TTM through Mar 2026 was 0.15%, a 18.0% increase from a year earlier, with the FY2025 full-year figure at 0.21%, up 30.0% from the prior year.
• Return on Sales for Q1 2026 stood at 0.29%, down from 0.13% in the prior quarter.
• Over the last five years, Return on Sales for TCRX reached as high as 0.04% in Q4 2023 and fell as low as 0.7% in Q4 2024.
• Historically, Return on Sales has averaged 0.2% across 5 years, with a median of 0.12% in 2025.
• Across the five-year window, Return on Sales sank 67 bps in 2024 and soared 58 bps in 2025, its largest moves.
• Year by year, Return on Sales stood at 0.06% in 2022, then soared by 45 bps to 0.04% in 2023, then slumped by 1907 bps to 0.7% in 2024, then surged by 82 bps to 0.13% in 2025, then tumbled by 133 bps to 0.29% in 2026.
• Per Business Quant data, the three most recent Return on Sales figures were 0.29% in Q1 2026, 0.13% in Q4 2025, and 0.14% in Q3 2025.